Journal of Clinical Oncology, Vol 16, 3362-3368, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

V Valero, SE Jones, DD Von Hoff, DJ Booser, RG Mennel, PM Ravdin, FA Holmes, Z Rahman, MW Schottstaedt, JK Erban, L Esparza-Guerra, RH Earhart, GN Hortobagyi and HA Burris 3rd
The University of Texas M.D. Anderson Cancer Center, Houston 77030- 4095, USA. vvalero@mdacc.org

PURPOSE: To evaluate the efficacy and safety of docetaxel in patients with paclitaxel-resistant metastatic breast cancer (MBC). PATIENTS AND METHODS: Docetaxel (100 mg/m2) was administered every 3 weeks to 46 patients registered at four centers. Patients had previously received < or = two chemotherapy regimens for MBC. All patients had progressive disease while receiving paclitaxel therapy. Treatment was repeated until there was evidence of disease progression or for a maximum of three cycles after best response. RESULTS: Objective responses were seen in eight of 44 assessable patients (18.1%; 95% confidence interval [CI], 6.7% to 29.5%). Seven patients had partial responses and one patient responded completely. Response rates were not significantly different by previously received paclitaxel dose or resistance. No responses were seen in 12 patients who had previously received paclitaxel by 24-hour infusion, but the response rate in 32 patients who had received paclitaxel by 1- to 3-hour infusion was 25%. The median response duration was 29 weeks and the median time to disease progression was 10 weeks. Median survival was 10.5 months. Clinically significant (severe) adverse events included neutropenic fever (24% of patients), asthenia (22%), infection (13%), stomatitis (9%), neurosensory changes (7%), myalgia (7%), and diarrhea (7%). CONCLUSION: Docetaxel is active in patients with paclitaxel-resistant breast cancer, particularly in those who failed to respond to brief infusions of paclitaxel. Response rates were comparable to or better than those seen with other therapies for patients with paclitaxel-resistant MBC. This confirms preclinical studies, which indicated only partial cross- resistance between paclitaxel and docetaxel.

This article has been cited by other articles:

				V. Dieras, S. Limentani, G. Romieu, M. Tubiana-Hulin, A. Lortholary, P. Kaufman, V. Girre, M. Besenval, and V. Valero Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy Ann. Onc., July 1, 2008; 19(7): 1255 - 1260. [Abstract] [Full Text] [PDF]

				E. Thomas, J. Tabernero, M. Fornier, P. Conte, P. Fumoleau, A. Lluch, L. T. Vahdat, C. A. Bunnell, H. A. Burris, P. Viens, et al. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer J. Clin. Oncol., August 10, 2007; 25(23): 3399 - 3406. [Abstract] [Full Text] [PDF]

				S. Verma and M. Clemons First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy Oncologist, July 1, 2007; 12(7): 785 - 797. [Abstract] [Full Text] [PDF]

				M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]

				V. K. Singh, Y. Zhou, J. A. Marsh, V. N. Uversky, J. D. Forman-Kay, J. Liu, and Z. Jia Synuclein-{gamma} Targeting Peptide Inhibitor that Enhances Sensitivity of Breast Cancer Cells to Antimicrotubule Drugs Cancer Res., January 15, 2007; 67(2): 626 - 633. [Abstract] [Full Text] [PDF]

				K. Gelmon, A. Chan, and N. Harbeck The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer Oncologist, September 1, 2006; 11(suppl_1): 42 - 51. [Abstract] [Full Text] [PDF]

				S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, et al. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5542 - 5551. [Abstract] [Full Text] [PDF]

				J. A. Low, S. B. Wedam, J. J. Lee, A. W. Berman, A. Brufsky, S. X. Yang, M. S. Poruchynsky, S. M. Steinberg, N. Mannan, T. Fojo, et al. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer J. Clin. Oncol., April 20, 2005; 23(12): 2726 - 2734. [Abstract] [Full Text] [PDF]

				C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]

				J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann. Onc., August 1, 2004; 15(8): 1274 - 1283. [Abstract] [Full Text] [PDF]

				J. Gligorov and J. P. Lotz Preclinical Pharmacology of the Taxanes: Implications of the Differences Oncologist, June 2, 2004; 9(suppl_2): 3 - 8. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti and A. T. Turrisi III Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Oncologist, August 1, 2003; 8(4): 361 - 374. [Abstract] [Full Text] [PDF]

				J. C. Trent, V. Valero, D. J. Booser, L. T. Esparza-Guerra, N. Ibrahim, Z. Rahman, L. Vernillet, S. Patel, C. L. David, J. L. Murray, et al. A Phase I Study of Docetaxel Plus Cyclophosphamide in Solid Tumors followed by a Phase II Study as First-Line Therapy in Metastatic Breast Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2426 - 2434. [Abstract] [Full Text] [PDF]

				A. D. Seidman, J. O'Shaughnessy, and J.-L. Misset Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer? Oncologist, December 1, 2002; 7(90006): 20 - 28. [Abstract] [Full Text] [PDF]

				D. Toppmeyer, A. D. Seidman, M. Pollak, C. Russell, K. Tkaczuk, S. Verma, B. Overmoyer, V. Garg, E. Ette, M. W. Harding, et al. Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel Clin. Cancer Res., March 1, 2002; 8(3): 670 - 678. [Abstract] [Full Text] [PDF]

				E. Rivera, L. Sutton, B. Colwell, M. Graham, D. Frye, M. Somerville, H. S. Conklin, C. McGuirt, J. Levin, and G. N. Hortobagyi Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer J. Clin. Oncol., February 15, 2002; 20(4): 987 - 993. [Abstract] [Full Text] [PDF]

				A. A. Garcia, C. G. Leichman, H. J. Lenz, J. Baranda, R. Lujan, Y. Casagrande, and L. Leichman Phase II Trial of Outpatient Schedule of Paclitaxel in Patients with Previously Untreated Metastatic, Measurable Adenocarcinoma of the Stomach Jpn. J. Clin. Oncol., June 1, 2001; 31(6): 275 - 278. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]

				C. Huisman, E. F. Smit, G. Giaccone, and P. E. Postmus Second-Line Chemotherapy in Relapsing or Refractory Non-Small-Cell Lung Cancer: A Review J. Clin. Oncol., November 1, 2000; 18(21): 3722 - 3730. [Abstract] [Full Text] [PDF]

				D. Frame Introduction to taxane pharmacokinetics and pharmacodynamics Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S23 - S27. [Abstract] [PDF]

				C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739. [Abstract] [Full Text] [PDF]

				J. Alexandre, P. Bleuzen, J. Bonneterre, W. Sutherland, J. L. Misset, J.-P. Guastalla, P. Viens, S. Faivre, A. Chahine, M. Spielman, et al. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients J. Clin. Oncol., February 1, 2000; 18(3): 562 - 562. [Abstract] [Full Text] [PDF]